Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.70 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.48 |
| ▸ | TNIK | Q9UKE5 | 5/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.44 |
| ▸ | SGK1 | O00141 | 1/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.41 |
| ▸ | IL2 | P60568 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22922481 | 1.00 | MAP4K1 (0.70) | MAP4K1MAP3K11TNIKPIK3CGSGK1 | |
| SCHEMBL21592906 | 0.95 | MAP4K1 (0.75) | MAP4K1MAP3K11TNIKPIK3CGIL2 | |
| SCHEMBL21592913 | 0.95 | MAP4K1 (0.75) | MAP4K1MAP3K11TNIKPIK3CGIL2 | |
| SCHEMBL21592845 | 0.88 | MAP4K1 (0.68) | MAP4K1MAP3K11TNIKPIK3CGIL2 | |
| SCHEMBL21592633 | 0.88 | MAP4K1 (0.68) | MAP4K1MAP3K11TNIKPIK3CGIL2 | |
| SCHEMBL21592634 | 0.88 | MAP4K1 (0.68) | MAP4K1MAP3K11TNIKPIK3CGIL2 | |
| SCHEMBL21593057 | 0.88 | MAP4K1 (0.66) | MAP4K1MAP3K11TNIKPIK3CGCAMKK2 | |
| SCHEMBL21592569 | 0.87 | MAP4K1 (0.62) | MAP4K1MAP3K11TNIKSGK1CAMKK2 | |
| SCHEMBL21592521 | 0.84 | MAP4K1 (0.60) | MAP4K1MAP3K11TNIKPIK3CGSGK1 | |
| SCHEMBL21592566 | 0.83 | MAP4K1 (0.65) | MAP4K1MAP3K11TNIKPIK3CGSGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021013083-A1 | TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-01-28 | — | — | WO | disclosed |